115 related articles for article (PubMed ID: 11910658)
1. Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems.
Buch AB; Shen LZ; Kelly SC; Russell DA; Sahota RS; Bixler CA; Moehrke W; Powell JH
Climacteric; 1999 Dec; 2(4):248-53. PubMed ID: 11910658
[TBL] [Abstract][Full Text] [Related]
2. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
[TBL] [Abstract][Full Text] [Related]
3. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
4. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
Rohr UD; Ehrly AM; Kuhl H
Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
[TBL] [Abstract][Full Text] [Related]
5. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.
Reginster JY; Albert A; Deroisy R; Colette J; Vrijens B; Blacker C; Brion N; Caulin F; Mayolle C; Regnard A; Scholler R; Franchimont P
Maturitas; 1997 Jun; 27(2):179-86. PubMed ID: 9255753
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.
Good WR; John VA; Ramirez M; Higgins JE
Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854
[TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women.
Baracat E; Haidar M; Castelo A; Tufik S; de Lima GR; Vieira JG; Peloso U; Casoy J
Maturitas; 1996 Apr; 23(3):285-91. PubMed ID: 8794422
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
9. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
Reginster JY; Donazzolo Y; Brion N; Lins R
Climacteric; 2000 Sep; 3(3):168-75. PubMed ID: 11910618
[TBL] [Abstract][Full Text] [Related]
10. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of oestradiol from the Alora (0.1 mg/day) oestradiol matrix transdermal delivery system compared with Estraderm (0.1 mg/day).
Bowen A; John VA; Ramirez ME; Good WR
J Obstet Gynaecol; 1998 Nov; 18(6):575-80. PubMed ID: 15512184
[TBL] [Abstract][Full Text] [Related]
12. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal women experiencing menopausal symptoms. Alora Study Group.
Good WR; John VA; Ramirez M; Higgins JE
Clin Ther; 1996; 18(6):1093-105. PubMed ID: 9001826
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women.
Boyd RA; Zegarac EA; Eldon MA; Sedman AJ; Forgue ST
Biopharm Drug Dispos; 1996 Aug; 17(6):459-70. PubMed ID: 8866037
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jan; 34(1):57-64. PubMed ID: 10687883
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system.
Müller P; Botta L; Ezzet F
Eur J Clin Pharmacol; 1996; 51(3-4):327-30. PubMed ID: 9010707
[TBL] [Abstract][Full Text] [Related]
16. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.
Järvinen A; Bäckström A; Elfström C; Viitanen A
Maturitas; 2001 Apr; 38(2):189-96. PubMed ID: 11306208
[TBL] [Abstract][Full Text] [Related]
17. Application and maintenance habits do make a difference in adhesion of Alora transdermal systems.
Gomez-Panzani E; Williams MB; Kuznicki JT; Myers WR; Zoller SA; Bixler CA; Winkler LC
Maturitas; 2000 Apr; 35(1):57-64. PubMed ID: 10802401
[TBL] [Abstract][Full Text] [Related]
18. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara).
Taggart W; Dandekar K; Ellman H; Notelovitz M
Menopause; 2000; 7(5):364-9. PubMed ID: 10993035
[TBL] [Abstract][Full Text] [Related]
19. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
20. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: experimental results.
Rohr UD; Saeger-Lorenz K
J Pharm Sci; 2002 Mar; 91(3):810-21. PubMed ID: 11920767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
